Now is the time to make MART moves for asthma

The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe - four times that of Italy or the Netherlands. This is unsurprising, considering many patients still rely on their blue inhalers alone.

However:
• Blue inhalers don’t treat inflammation
• Brown inhalers don’t relieve symptoms quickly

First and foremost, the best inhaler is the inhaler the patient will use and identifying what this is should actively involve the patient.

This article is intended for professionals caring for asthma patients 12 years and over. The prescriber should check which inhalers are allowed for 12+ and which are for 18+.

We are grateful to Orion Pharma (UK) Ltd for sponsoring PCRS in developing resources for the Maintenance and Reliever Therapy (MART) in asthma project. The sponsor has had no input into the resource content.
Attachment Size
Now is the time to make MART moves for asthma 504.37 KB
Clinical Area
Asthma Inhaler devices
Category
PCRU
Listing Status
Current
Related PCRU Issue
Autumn/Winter 2024

You may also be interested in...

Maintenance and Reliever Therapy (MART) asthma action plan

Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers. 

Maintenance and Reliever Therapy (MART) top tips article

Now is the time to make MART moves for asthma.